Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Small Pharma Inc (OP: DMTTF ) N/A UNCHANGED Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Small Pharma Inc < Previous 1 2 3 4 5 6 7 8 Next > Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25 January 24, 2023 From Small Pharma Inc. Via GlobeNewswire Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous? January 11, 2023 Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its... Via Benzinga First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026 January 09, 2023 Study will compare the profile of intramuscular versus intravenous SPL026 administration From Small Pharma Inc. Via GlobeNewswire Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More December 28, 2022 Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries Via Benzinga This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage December 22, 2022 Short-acting psychedelics biotech company Small Pharma Inc. Via Benzinga Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property December 22, 2022 From Small Pharma Inc. Via GlobeNewswire Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing December 19, 2022 Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors... Via Benzinga How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study December 16, 2022 The University College London (UCL) is conducting a new research project called “Understanding Neuroplasticity Induced by Tryptamines (UNITy)” aimed at assessing brain changes and neuroplasticity... Via Benzinga First Patient Dosed in Small Pharma’s Drug Interaction Study December 15, 2022 Open-label study will assess the interaction between SSRI antidepressants and SPL026 From Small Pharma Inc. Via GlobeNewswire Small Pharma To Support University College London Research Project on Neuroplasticity December 14, 2022 Small Pharma will provide SPL026 for the brain-imaging study, which seeks to explore how psychedelic-induced brain changes impact cognition, behaviour and well-being From Small Pharma Inc. Via GlobeNewswire Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium December 08, 2022 From Small Pharma Inc. Via GlobeNewswire Psychedelic Stock Gainers And Losers From November 24, 2022 November 24, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 23, 2022 November 23, 2022 Via Benzinga Small Pharma to Participate in November Investor and Healthcare Conferences November 11, 2022 From Small Pharma Inc. Via GlobeNewswire Psychedelic Stock Gainers And Losers From November 8, 2022 November 08, 2022 GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 Via Benzinga Compass Pathways, Allied Among Top Psychedelic Movers Of Today November 07, 2022 GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44 Via Benzinga Psychedelic Stock Gainers And Losers From November 3, 2022 November 03, 2022 GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27 Via Benzinga Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today November 02, 2022 GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: Via Benzinga This Novel Short-Acting Psychedelic Compound Is Ready For First Phase 1 Clinical Try-Out October 31, 2022 Small Pharma Inc. Via Benzinga Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028 October 31, 2022 From Small Pharma Inc. Via GlobeNewswire Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today October 27, 2022 GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87 Via Benzinga Psychedelic Stock Gainers And Losers From October 26, 2022 October 26, 2022 GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18 Via Benzinga Psychedelic Stock Gainers And Losers From October 25, 2022 October 25, 2022 GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39 Via Benzinga Allied, Small Pharma Among Top Psychedelic Movers Of Today October 21, 2022 GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53 Via Benzinga This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More October 19, 2022 Short-acting psychedelics biotech firm Small Pharma Inc. Via Benzinga Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio October 19, 2022 From Small Pharma Inc. Via GlobeNewswire Psychedelic Stock Gainers And Losers From October 18, 2022 October 18, 2022 GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14 Via Benzinga Small Pharma's Q2 2023 Financial Results, 'Ultra Short-Acting Psychedelic Program' Underway October 18, 2022 Small Pharma Inc. (OTCQB: DMTTF), a biotech company developing short-acting psychedelic-assisted therapies for diverse mental health disorders, reported its financial results for the three and six... Via Benzinga Small Pharma Reports Fiscal Second Quarter 2023 Highlights October 14, 2022 From Small Pharma Inc. Via GlobeNewswire Small Pharma, Cybin Among Top Psychedelic Movers Of Today October 14, 2022 GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12 Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
